当前位置：
X-MOL 学术
›
Ther. Adva. Endocrinol. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Emerging pharmacological treatment options for MAFLD
Therapeutic Advances in Endocrinology and Metabolism ( IF 3.8 ) Pub Date : 2022-12-10 , DOI: 10.1177/20420188221142452 Ángela Rojas 1, 2 , Carmen Lara-Romero 3, 4 , Rocío Muñoz-Hernández 3, 5 , Sheila Gato 3, 5 , Javier Ampuero 3, 4, 5 , Manuel Romero-Gómez 1, 2, 6
Therapeutic Advances in Endocrinology and Metabolism ( IF 3.8 ) Pub Date : 2022-12-10 , DOI: 10.1177/20420188221142452 Ángela Rojas 1, 2 , Carmen Lara-Romero 3, 4 , Rocío Muñoz-Hernández 3, 5 , Sheila Gato 3, 5 , Javier Ampuero 3, 4, 5 , Manuel Romero-Gómez 1, 2, 6
Affiliation
Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitu...
中文翻译：
MAFLD 的新兴药物治疗选择
代谢功能障碍相关脂肪肝病 (MAFLD) 的患病率和发病率在全球范围内呈上升趋势。它与代谢合并症、肥胖、超重、2 型糖尿病有关……
更新日期：2022-12-12
中文翻译：
MAFLD 的新兴药物治疗选择
代谢功能障碍相关脂肪肝病 (MAFLD) 的患病率和发病率在全球范围内呈上升趋势。它与代谢合并症、肥胖、超重、2 型糖尿病有关……
京公网安备 11010802027423号